Golden Meditech and MD Anderson Form $20 Million Stem Cell Company

Golden Meditech, a Hong Kong company with a China cord blood banking subsidiary, formed an autoimmune-focused biotech, Cellenkos, with the University of Texas at MD Anderson Cancer Center. Cellenkos will combine the T-reg stem cell technology developed at the Anderson Center and Golden Meditech's banked cord blood samples. Golden Meditech, along with an unidentified strategic investor, invested $10 million in the newco and owns warrants to purchase an additional $10 million of shares. If they exercise the warrants, the investors will own 51% of Cellenkos. More details.... Stock Symbols: (HK: 00801; TW: 910801) Share this with colleagues: // //